Schering, Pfizer Responding To Investigations Of Managed Care Deals
Executive Summary
Schering-Plough is responding to a grand jury subpoena issued in March by the Philadelphia U.S. Attorney's Office focusing on whether "nominally priced" products and other free goods should have been included in Medicaid rebate calculations
You may also be interested in...
Abbott “Nominal Prices” Cited In Medco Suit; “Improper” Payments Alleged
Medco's access to "nominally priced" Abbott medicines is one example cited by the Philadelphia U.S. Attorney of an "inducement" accepted by the pharmacy benefit management company
Abbott “Nominal Prices” Cited In Medco Suit; “Improper” Payments Alleged
Medco's access to "nominally priced" Abbott medicines is one example cited by the Philadelphia U.S. Attorney of an "inducement" accepted by the pharmacy benefit management company
Schering Sets Aside $150 Mil. For Liabilities In Marketing Investigations
Schering-Plough is estimating its "minimum liability" in pending investigations of its marketing practices at the low end of recent settlements within the pharmaceutical industry